SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

July 27, 2020Synact Pharma meddelar utfall i optionslösen, tillförs totalt cirka 32,4 MSEKSynact Pharma meddelar utfall i optionslösen, tillförs totalt cirka 32,4 MSEK
July 27, 2020Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4
July 15, 2020SynAct Pharma meddelar sista dag för nyttjande av teckningsoptioner av serie TO 2
July 15, 2020SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis

All press releases

News

April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
October 28, 2019Redeye: Adding an indication
July 5, 2019Kliniska bevis för behandlingseffekter av melanokortiner vid reumatoid artrit

Calendar

October 8, 2020Sedermeradagen Gothenburg
October 26, 2020 - October 28, 2020Bio Europe 2020
November 16, 2020Sedermeradagen Stockholm

Subscribe to our press releases